Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Center for Biomedical Research

Neither a doctor nor a teaching hospital

Research payments

$1,138,300

195 payments

Through program year 2025, Center for Biomedical Research is reported as receiving $1,138,300 in research payments, across 195 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $344,613 76
2024 Research $193,715 56
2023 Research $113,357 1
2022 Research $166,346 14
2021 Research $1,986 1
2020 Research $100,366 24
2019 Research $217,916 23

Breakdown

Who paid Research payments · program years 2019–2025
  1. United Therapeutics Corporation $368,036 129 payments
  2. Biogen, Inc. $235,925 7 payments
  3. Eli Lilly and Company $167,548 4 payments
  4. Novo Nordisk AS $139,700 13 payments
  5. F. Hoffmann-La Roche AG $110,205 34 payments
  6. Pfizer Inc. $73,123 2 payments
  7. Helsinn Healthcare SA $27,762 5 payments
  8. Genentech, Inc. $16,000 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $151,735 2 payments
  2. Nn6535-4725 $139,700 13 payments
  3. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $131,504 2 payments
  4. A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) $104,312 29 payments
  5. A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $92,853 36 payments
  6. An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis $89,490 32 payments
  7. 1L Nsclc DX All Comer Non Squamous $79,468 21 payments
  8. Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD) $75,789 3 payments
  9. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $73,123 2 payments
  10. Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (Phinder) $35,143 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record